MAIDENHEAD, England,
February 28, 2013 /PRNewswire/ --
--Rare
Disease Day takes place on 28 February
2013 and this year's theme focuses on 'Rare Disorders
without Borders'--
--ViroPharma Incorporated is an international biopharmaceutical
company committed to supporting patients with serious diseases for
which there is an unmet medical need--
ViroPharma Incorporated (NASDAQ: VPHM), an international
biopharmaceutical company committed to supporting patients with
serious diseases for which there is an unmet medical need, today
announced its participation in the sixth international Rare Disease
Day. Rare Disease Day is coordinated by the European Organisation
for Rare Diseases (EURORDIS) and by the National Organization for
Rare Disorders (NORD) in the US and encourages patient
organisations from across the globe to organise awareness-raising
activities around this year's theme 'Rare Disorders without
Borders'.
This year's theme focuses on helping to drive cross-border
cooperation for diseases which affect only a few people in each
country and for which expertise is scarce and scattered. There are
more than 6,000 rare diseases affecting more than 60 million people
in Europe and the US
alone.[1] Most of these diseases are genetic, serious,
chronic and debilitating, and 50 percent of rare diseases touch
children.[1]
"ViroPharma is a proud member of EURORDIS and is delighted to be
participating in this year's Rare Disease Day. At ViroPharma, we
are committed to improving the lives of patients and believe in the
value of this year's theme to create a network of solidarity for
patients living with these diseases," said Thierry Darcis, Vice President, General Manager,
ViroPharma, Europe. "We understand
the isolation felt by many people living with rare diseases, and
will continue to deliver solutions that address critical gaps in
care for patients living with few, if any, clinical treatment
options."
ViroPharma provides novel treatment solutions for patients
living with rare diseases including hereditary angioedema, adrenal
insufficiency, prolonged, acute, convulsive seizures, and
Clostridium difficile infection.
As part of its commitment to improving the lives of patients
with rare diseases in Europe,
ViroPharma sponsors and funds educational initiatives
including:
- The Hereditary Angioedema Burden of Illness Study in
Europe (HAE-BOIS-Europe), an
innovative, patient-centric, multi-country study of the humanistic
and economic burden of HAE to address and improve current knowledge
gaps surrounding the condition.
- The PERFECT™ (Practices in Emergency and Rescue medication For
Epilepsy managed with Community administered Therapy) Initiative,
which aims to document and communicate first of its kind data on
the impact of conflict of policy, guidelines and actual practice in
the care of prolonged, acute, convulsive seizures in infants,
toddlers, children and adolescents in the non-hospital
setting.
ViroPharma Incorporated is based in Exton, Pennsylvania, US, and also has offices
in Canada and in eight European
countries including Belgium,
France, Germany, Italy, Spain,
Sweden, Switzerland and the United Kingdom. ViroPharma is continuing to
grow its footprint and presence in Europe, and to support this growth set up its
first European subsidiary in 2007, leveraging in Europe the company's expertise in the
development and commercialisation of biotechnology products, and in
business development.
Forward Looking
Statements
Certain statements in this press release contain forward-looking
statements that involve a number of risks and uncertainties.
Forward-looking statements provide our current expectations or
forecasts of future events, including our ability to continue to
deliver solutions that address critical gaps in care for patients
living with few, if any, clinical treatment options. There can be
no assurance that we will be successful in our efforts to continue
to deliver solutions in the future. These factors, and other
factors, including, but not limited to those described in our
annual report on Form 10-K for the year ended December 31, 2012 and quarterly reports on Form
10-Q filed with the Securities and Exchange Commission for the
periods ended March 31, 2012,
June 30, 2012 and September 30, 2012, could cause future results to
differ materially from the expectations expressed in this press
release. The forward-looking statements contained in this press
release are made as of the date hereof and may become outdated over
time. ViroPharma does not assume any responsibility for updating
any forward-looking statements. These forward-looking statements
should not be relied upon as representing our assessments as of any
date subsequent to the date of this press release.
About ViroPharma
Incorporated
ViroPharma Incorporated is an international biopharmaceutical
company committed to developing and commercialising novel solutions
for physician specialists to address unmet medical needs of
patients living with diseases that have few, if any, clinical
therapeutic options, including C1 esterase inhibitor deficiency,
treatment of seizures in children and adolescents, adrenal
insufficiency, and C. difficile infection (CDI). Our goal is
to provide rewarding careers to employees, to create new standards
of care in the way serious diseases are treated, and to build
international partnerships with the patients, advocates, and
healthcare professionals we serve.
ViroPharma routinely posts information, including press
releases, which may be important to investors in the investor
relations and media sections of our company's website,
http://www.viropharma.com/. The company encourages investors to
consult these sections for more information on ViroPharma and our
business.
References
1. Rare Disorders without Borders.
Available at:
http://www.rarediseaseday.org/article/rare-disorders-solidarity-has-no-border.
Last accessed January 2013.